Neratinibirreversibly binds to the intracellular domain of HER2, inhibiting signalingpathways that promote tumor growth [15].Clinical trials demonstrated that adding neratinib to trastuzumab-based therapycould improve disease-free survival rates in patients with early-stage HER2-positiveBC [16][17]. The gene discussed is ERBB2; the disease is neoplasm.